J. Mullol

406 total citations
7 papers, 315 citations indexed

About

J. Mullol is a scholar working on Otorhinolaryngology, Rheumatology and Epidemiology. According to data from OpenAlex, J. Mullol has authored 7 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Otorhinolaryngology, 3 papers in Rheumatology and 2 papers in Epidemiology. Recurrent topics in J. Mullol's work include Sinusitis and nasal conditions (4 papers), Otitis Media and Relapsing Polychondritis (3 papers) and Mycobacterium research and diagnosis (2 papers). J. Mullol is often cited by papers focused on Sinusitis and nasal conditions (4 papers), Otitis Media and Relapsing Polychondritis (3 papers) and Mycobacterium research and diagnosis (2 papers). J. Mullol collaborates with scholars based in United States, Belgium and Spain. J. Mullol's co-authors include David Price, Barbara P. Yawn, Mike Thomas, Valerie J. Lund, Michiko Okayama, María José García Mérida, James N. Baraniuk, James H. Shelhamer, Jens Lundgren and Isam Alobid and has published in prestigious journals such as Journal of Clinical Investigation, Allergy and Otolaryngology.

In The Last Decade

J. Mullol

7 papers receiving 296 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Mullol United States	6	154	146	125	94	73	7	315
Thomas Runer Sweden	9	143 0.9×	235 1.6×	58 0.5×	68 0.7×	161 2.2×	14	442
Nadine Mrad Australia	9	185 1.2×	149 1.0×	121 1.0×	199 2.1×	36 0.5×	9	360
Alice Z. Maxfield United States	10	126 0.8×	88 0.6×	61 0.5×	81 0.9×	54 0.7×	26	239
Saltanat Ualiyeva United States	6	10 0.1×	143 1.0×	53 0.4×	79 0.8×	52 0.7×	12	369
Sina Koochakzadeh United States	9	195 1.3×	55 0.4×	114 0.9×	180 1.9×	11 0.2×	13	304
T. Godthelp Netherlands	10	19 0.1×	329 2.3×	330 2.6×	19 0.2×	97 1.3×	11	403
F.A. Romero United States	10	14 0.1×	420 2.9×	286 2.3×	18 0.2×	222 3.0×	21	573
Karine Clearie United Kingdom	9	13 0.1×	271 1.9×	88 0.7×	17 0.2×	244 3.3×	11	333
J Tóth Austria	11	14 0.1×	186 1.3×	229 1.8×	34 0.4×	43 0.6×	19	301
G Baktai Hungary	3	20 0.1×	46 0.3×	13 0.1×	19 0.2×	320 4.4×	3	359

Countries citing papers authored by J. Mullol

Since Specialization

Citations

This map shows the geographic impact of J. Mullol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Mullol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Mullol more than expected).

Fields of papers citing papers by J. Mullol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Mullol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Mullol. The network helps show where J. Mullol may publish in the future.

Co-authorship network of co-authors of J. Mullol

This figure shows the co-authorship network connecting the top 25 collaborators of J. Mullol. A scholar is included among the top collaborators of J. Mullol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Mullol. J. Mullol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Gevaert, Philippe, Peter W. Hellings, J. Mullol, et al.. (2020). Omalizumab is associated with a reduced need for surgery in patients with nasal polyposis. Allergy. 75. 108–108. 1 indexed citations

2.

Gevaert, Philippe, J. Mullol, Rui Zhao, et al.. (2020). D202 CONTINUED SAFETY/EFFICACY OF OMALIZUMAB IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS: AN OPEN-LABEL EXTENSION STUDY. Annals of Allergy Asthma & Immunology. 125(5). S15–S15. 5 indexed citations

3.

Gevaert, Philippe, Claus Bachert, J. Mullol, et al.. (2019). D450 OMALIZUMAB EFFICACY AND SAFETY IN NASAL POLYPOSIS: RESULTS FROM TWO PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS. Annals of Allergy Asthma & Immunology. 123(5). S17–S17. 11 indexed citations

4.

Alobid, Isam, et al.. (2012). Oral and intranasal steroid treatments improve nasal patency and paradoxically increase nasal nitric oxide in patients with severe nasal polyposis. Rhinology Journal. 50(2). 171–177. 32 indexed citations

5.

Thomas, Mike, et al.. (2008). EPOS Primary Care Guidelines: European Position Paper on the Primary Care Diagnosis and Management of Rhinosinusitis and Nasal Polyps 2007 — a summary. Primary Care Respiratory Journal. 17(2). 79–89. 147 indexed citations

6.

Alobid, Isam, et al.. (2005). Severe Nasal Polyposis and Its Impact on Quality of Life. Otolaryngology. 133(2). P256–P256. 17 indexed citations

7.

Baraniuk, James N., Jens Lundgren, Michiko Okayama, et al.. (1990). Vasoactive intestinal peptide in human nasal mucosa.. Journal of Clinical Investigation. 86(3). 825–831. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact